1. Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.
- Author
-
Haghikia, Aiden, Perrech, Moritz, Pula, Bartosz, Ruhrmann, Sabrina, Potthoff, Anja, Brockmeyer, Norbert H, Goelz, Susan, Wiendl, Heinz, Lindå, Hans, Ziemssen, Tjalf, Baranzini, Sergio E, Käll, Tor-Björn, Bengel, Dietmar, Olsson, Tomas, Gold, Ralf, and Chan, Andrew
- Subjects
CD4-Positive T-Lymphocytes ,Humans ,Leukoencephalopathy ,Progressive Multifocal ,Autoimmune Diseases ,Antibodies ,Monoclonal ,Case-Control Studies ,Immunity ,Cellular ,Immunocompromised Host ,Leukoencephalopathy ,Progressive Multifocal ,Antibodies ,Monoclonal ,Immunity ,Cellular ,General Science & Technology - Abstract
BackgroundProgressive multifocal leukoencephalopathy (PML) is an opportunistic central nervous system- (CNS-) infection that typically occurs in a subset of immunocompromised individuals. An increasing incidence of PML has recently been reported in patients receiving monoclonal antibody (mAb) therapy for the treatment of autoimmune diseases, particularly those treated with natalizumab, efalizumab and rituximab. Intracellular CD4(+)-ATP-concentration (iATP) functionally reflects cellular immunocompetence and inversely correlates with risk of infections during immunosuppressive therapy. We investigated whether iATP may assist in individualized risk stratification for opportunistic infections during mAb-treatment.Methodology/principal findingsiATP in PHA-stimulated, immunoselected CD4(+)-cells was analyzed using an FDA-approved assay. iATP of mAb-associated PML (natalizumab (n = 8), rituximab (n = 2), efalizumab (n = 1)), or other cases of opportunistic CNS-infections (HIV-associated PML (n = 2), spontaneous PML, PML in a psoriasis patient under fumaric acids, natalizumab-associated herpes simplex encephalitis (n = 1 each)) was reduced by 59% (194.5±29 ng/ml, mean±SEM) in comparison to healthy controls (HC, 479.9±19.8 ng/ml, p
- Published
- 2011